2022
Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics
Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics. JAMA Network Open 2022, 5: e2236904. PMID: 36251291, PMCID: PMC9577676, DOI: 10.1001/jamanetworkopen.2022.36904.Peer-Reviewed Original ResearchConceptsTobacco use disorderHIV clinicOpioid use disorderUse disordersAlcohol use disorderAddiction treatmentControl periodImplementation facilitationAdoption of medicationsMulticomponent implementation strategyProvision of MOUDUS HIV clinicsMaintenance periodElectronic health record dataHealth record dataEvaluation periodAdult patientsMean ageClinical trialsMAIN OUTCOMEClinicMOUDPatientsDisordersPatient incentives
2020
Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder
Muvvala SB, O'Malley SS, Rosenheck R. Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder. American Journal On Addictions 2020, 30: 55-64. PMID: 32805083, DOI: 10.1111/ajad.13089.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlcohol DeterrentsAlcoholismAmbulatory CareDepressive Disorder, MajorFemaleHospitalizationHumansIll-Housed PersonsMaleMental Health ServicesMiddle AgedMorbidityNaltrexonePsychotherapyPsychotropic DrugsSchizophreniaSocioeconomic FactorsUnited StatesUnited States Department of Veterans AffairsVeteransConceptsAlcohol use disorderUse of naltrexonePsychotropic prescription fillsPrescription fillsUse disordersOutpatient mental health servicesCorrelates of initiationMedical-surgical hospitalizationMultiple psychiatric morbiditiesEfficacy of naltrexonePsychotropic medication useVeterans Health AdministrationPsychiatric outpatient servicesConcurrent psychiatric disordersMajor depressive disorderMental health servicesProportion of veteransNaltrexone initiationMedication usePsychiatric morbidityDepressive disorderImportant patientPsychiatric hospitalizationMultinomial logistic regressionOutpatient servicesEffects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline
Miranda R, O’Malley S, Padovano H, Wu R, Falk DE, Ryan ML, Fertig JB, Chun TH, Muvvala SB, Litten RZ. Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline. Alcohol Clinical And Experimental Research 2020, 44: 1431-1443. PMID: 32363592, PMCID: PMC7572549, DOI: 10.1111/acer.14352.Peer-Reviewed Original ResearchConceptsAlcohol use disorderEffects of vareniclineAlcohol cue reactivityClinical trialsCue-reactivity paradigmAlcohol useCue reactivityUse disordersHuman laboratoryAlcohol cue-induced cravingSubsequent treatment outcomesΑ4β2 nicotinic acetylcholine receptorsCue-induced alcoholAlcohol cue reactivity paradigmCue-induced cravingNicotinic acetylcholine receptorsHeavy alcohol useCue-elicited cravingHuman laboratory paradigmTreatment outcomesVareniclinePlaceboProspective associationsAlcohol cravingAcetylcholine receptors
2019
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Bold KW, Zweben A, Fucito LM, Piepmeier ME, Muvvala S, Wu R, Gueorguieva R, O'Malley SS. Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. Alcohol Clinical And Experimental Research 2019, 43: 937-944. PMID: 30817018, PMCID: PMC7039307, DOI: 10.1111/acer.13994.Peer-Reviewed Original ResearchConceptsEnd of treatmentAlcohol use disorderHeavy drinking daysMedical managementCigarette smokingComorbid cigarette smokingUse disordersDrinking daysCo-occurring alcohol use disorderHigh ratePlacebo-controlled trialBetter clinical outcomesAssessment of alcoholPercent of participantsVarenicline treatmentClinical outcomesSmoking abstinenceParallel groupClinical trialsTimeline FollowVareniclineSmoking behaviorAlcohol treatmentPosttreatment outcomesMultisite trial
2018
Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial
O’Malley S, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM, Bold KW, Petrakis I, Muvvala S, Jatlow P, Gueorguieva R. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry 2018, 75: 129-138. PMID: 29261824, PMCID: PMC5838706, DOI: 10.1001/jamapsychiatry.2017.3544.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMedical managementUse disordersCigarette smokingWeek 9Varenicline tartrateEfficacy of vareniclinePlacebo-controlled trialBehavioral health risksComorbid cigarette smokingRace/ethnicityAlcohol dependence criteriaSmoking 2Medication adherenceOutpatient clinicPlacebo pillsMean ageEligible participantsSmoking abstinenceClinical trialsParallel groupPlaceboMAIN OUTCOMEVareniclineWeek 13